Henry Schein Reports Fourth Quarter 2020 Financial Results From Continuing Operations

Rhea-AI Summary

Henry Schein reported fourth quarter 2020 net sales of $3.2 billion, an increase of 18.6% from Q4 2019, driven by demand for PPE and COVID-19 products. GAAP net income was $141.9 million or $0.99 per diluted share, down from $330.6 million or $2.25 per diluted share a year earlier. Non-GAAP net income rose slightly to $143.6 million or $1.00 per diluted share. Operating margins suffered from inventory adjustments and an $18.1 million impairment charge. 2021 non-GAAP EPS guidance is set at or above $3.51, excluding potential restructuring costs.

Positive

• Fourth quarter net sales increased by 18.6% to $3.2 billion, driven by strong performance in PPE and COVID-19 related products.
• Non-GAAP net income rose to $143.6 million or $1.00 per diluted share, up from $143.0 million or $0.97 per diluted share in the previous year.
• Medical sales surged by 48.5% to $1.2 billion, bolstered by demand for COVID-19 tests.
• 2021 non-GAAP diluted EPS guidance set at or above 2019 levels, indicating potential growth.

Negative

• GAAP net income decreased significantly from $330.6 million to $141.9 million, reflecting challenges in the pandemic.
• Operating margin negatively impacted by inventory adjustments and an $18.1 million intangible asset impairment charge.

Henry Schein, Inc. (Nasdaq: HSIC), the world’s largest provider of health care solutions to office-based dental and medical practitioners, today reported fourth quarter financial results from continuing operations. Results from continuing operations exclude contributions from Henry Schein’s former Animal Health business, which was spun off in February 2019 to form a new publicly traded company, Covetrus (Nasdaq: CVET).

Total net sales for the quarter ended December 26, 2020, were $3.2 billion, an increase of 18.6% compared with the fourth quarter of 2019, driven by sales of personal protective equipment (PPE) and COVID-19 related products. The 18.6% increase included 17.1% internal growth in local currencies, 0.3% growth from acquisitions and 1.2% growth related to foreign currency exchange. (See Exhibit A for details of sales growth).

GAAP net income attributable to Henry Schein, Inc. from continuing operations for the fourth quarter of 2020 was $141.9 million, or $0.99 per diluted share, compared with prior-year GAAP net income from continuing operations of $330.6 million, or $2.25 per diluted share, which included a net gain on sale of equity investments of approximately $186.8 million, or $1.27 per diluted share. Non-GAAP net income from continuing operations for the fourth quarter of 2020 was $143.6 million, or $1.00 per diluted share, compared with prior-year non-GAAP net income from continuing operations of $143.0 million, or $0.97 per diluted share. Exhibit B provides a reconciliation of GAAP net income and diluted EPS from continuing operations to non-GAAP net income and diluted EPS from continuing operations. Operating margin was unfavorably impacted by significant inventory adjustments associated with PPE and COVID-19 related products, and lower supplier rebates, partially offset by lower expenses as a percentage of sales. Operating margin was also negatively impacted by a non-cash intangible asset impairment charge of approximately $18.1 million, or $0.07 per diluted share. Both GAAP and non-GAAP net income for the fourth quarter 2020 were favorably impacted by income tax resolutions in the U.S. and internationally, which lowered income tax expense by approximately $14.6 million, or $0.10 per diluted share.

“Against the backdrop of a most challenging year in our history due to the COVID-19 pandemic, with an unprecedented human toll and economic impact worldwide, Henry Schein’s unwavering focus on our customers, along with our resilience and agility, enabled us to deliver fourth quarter total net sales growth of 18.6%. In addition, we delivered record total net sales growth for the second half of 2020 as our end markets have rebounded, and we recognize the commitment and sacrifice of our Team Schein Members globally,” said Stanley M. Bergman, Chairman of the Board and Chief Executive Officer of Henry Schein. “We were successful in supporting practices that were initially open for emergency services and also assisting customers preparing to restore practices to increased operating capacity as restrictions eased. Over time, we expect that patient traffic will improve to pre-COVID-19 levels.”

“I remain confident that Henry Schein is well-positioned for future continued success given the breadth of our products, services and support across the global dental and medical markets,” Mr. Bergman continued.

Dental sales for the fourth quarter of 2020 of $1.8 billion increased 7.2% versus the prior-year. In local currencies, internally generated sales increased 5.1% with 0.4% growth from acquisitions and 1.7% growth related to foreign currency exchange. The 5.1% internal growth in local currencies included a decline of 0.7% in North America and an increase of 14.2% internationally.

Global dental consumable merchandise internal sales increased by 10.0% in local currencies. Excluding PPE and COVID-19 related products, sales increased by 5.0%. In North America, dental consumable merchandise internal sales in local currencies increased 5.3%, or 0.4% excluding PPE and COVID-19 related products, and dental equipment internal sales in local currencies decreased 13.2%. Dental equipment sales performance was impacted by a difficult prior-year comparison. In addition, we believe some practices potentially held off on year-end equipment purchases as U.S. tax incentives may be more favorable in 2021. Internationally, dental consumable merchandise internal sales in local currencies increased 16.7%, or 11.4% excluding PPE and COVID-19 related products, and dental equipment internal sales in local currencies increased 6.8%.

“We reported strong overall global dental sales growth in the fourth quarter. High-acuity procedures, including dental specialties and restorative procedures, also contributed to year-over-year sales growth. The 5.0% quarterly growth rate for global dental consumable sales is among the highest recorded by Henry Schein since 2017. International sales results for both consumable merchandise and equipment were strong. Dental patient traffic has remained at stable levels compared to the third quarter of 2020, even in countries experiencing more stringent lockdown rules, with the exception of the U.K.,” noted Mr. Bergman.

Medical sales for the fourth quarter of 2020 of $1.2 billion increased 48.5% compared with the same period last year, consisting of 48.2% growth in local currencies with 0.3% growth related to foreign currency exchange. There was no acquisition growth in the quarter.

“Our Medical business experienced strong year-over-year sales growth in the fourth quarter driven by continued demand for PPE and COVID-19 related products, most specifically for COVID-19 test sales. For the second quarter in a row, our global Medical business has achieved over $1 billion in quarterly sales,” remarked Mr. Bergman. “Excluding sales of PPE and COVID-19 related products, sales increased by approximately 3.6%. We believe solid COVID-19 test sales growth is likely to continue while COVID-19 cases remain at relatively high levels.”

Technology and Value-Added Services sales of $138.7 million increased 1.2% versus the prior-year. The 1.2% increase included a decline of 0.7% in internal local currency sales, offset by 1.2% growth from acquisitions and 0.7% growth related to foreign currency exchange.

“Technology and Value-Added Services sales in the quarter were impacted by lower transactional revenue associated with a lower number of patient visits compared to pre-COVID-19 practice volume. We also experienced a difficult prior-year comparison that benefited from hardware upgrades as we helped transition customers to address new operating system requirements. In addition, lower dental equipment sales volume in North America impacted our hardware revenue,” said Mr. Bergman. “We were pleased with solid growth in our Dentrix Ascend cloud-based software and North America financial services sales. We continue to invest in our technology solutions, including Henry Schein One, which is a key resource to help drive business success for dental practices.”

2020 Financial Results

Total net sales for 2020 were $10.1 billion, an increase of 1.3% compared with 2019. In local currencies, internally generated sales increased 0.8%. Changes in foreign currency exchange resulted in a 0.1% decline in sales, while acquisitions contributed 0.6% to growth.

GAAP net income attributable to Henry Schein, Inc. from continuing operations for 2020 was $402.8 million, or $2.81 per diluted share, compared with GAAP net income from continuing operations for 2019 of $700.7 million, or $4.69 per diluted share. Non-GAAP net income from continuing operations for 2020 was $425.3 million, or $2.97 per diluted share, compared with non-GAAP net income from continuing operations for 2019 of $523.6 million, or $3.51 per diluted share. The decline in non-GAAP net income was driven by COVID-19, primarily during the second quarter. Exhibit B provides a reconciliation of GAAP net income and diluted EPS from continuing operations to non-GAAP net income and diluted EPS from continuing operations.

Stock Repurchase Plan

Prior to the suspension of the Company’s share repurchase program due to COVID-19, for fiscal year 2020 Henry Schein repurchased approximately 1.2 million shares of common stock at an average price of $61.49 for a total of $73.8 million. At fiscal year-end, Henry Schein had $201 million authorized and available for future stock repurchases. Pursuant to amendments to certain credit facilities, Henry Schein is restricted from engaging in stock repurchases until the Company reports second-quarter 2021 financial results.

Financial Guidance

Henry Schein today introduced guidance for 2021 non-GAAP diluted EPS from continuing operations. At this time, the Company is not providing guidance for 2021 GAAP diluted EPS from continuing operations as it is unable to provide an accurate estimate of expenses related to an ongoing restructuring initiative in 2021. Financial guidance is as follows:

• 2021 non-GAAP diluted EPS from continuing operations attributable to Henry Schein, Inc. is expected to be at or above 2019 non-GAAP diluted EPS from continuing operations of $3.51. The Company believes the comparison to 2019 non-GAAP diluted EPS from continuing operations is most appropriate given the impact of COVID-19 on 2020 results of operations.

• Guidance for 2021 non-GAAP diluted EPS attributable to Henry Schein, Inc. is for current continuing operations as well as completed or previously announced acquisitions, and does not include the impact of potential future acquisitions, if any, restructuring expenses or share repurchases. Guidance also assumes foreign exchange rates that are generally consistent with current levels, and that end markets remain stable and are consistent with current market conditions. Guidance does not assume any material market changes associated with COVID-19.

Adjustments to Projected 2021 Non-GAAP Diluted EPS

The Company has provided guidance for 2021 non-GAAP diluted EPS from continuing operations, as noted above. A reconciliation to the Company’s projected 2021 diluted EPS from continuing operations prepared on a GAAP basis is not provided because the Company is unable to provide without unreasonable effort an estimate of costs related to an ongoing restructuring program to mitigate stranded costs and drive additional operating efficiencies, including the corresponding tax effect that will be included in the Company’s 2021 diluted EPS from continuing operations prepared on a GAAP basis. The inability to provide these reconciliations is due to the uncertainty and inherent difficulty of predicting the occurrence, magnitude, financial impact, and the timing of related costs. Management does not believe these items are representative of the Company’s underlying business performance. For the same reasons, the Company is unable to address the probable significance of the unavailable information, which could be material to future results.

Fourth Quarter 2020 Conference Call Webcast

The Company will hold a conference call to discuss fourth quarter 2020 financial results today, beginning at 10:00 a.m. Eastern time. Individual investors are invited to listen to the conference call through Henry Schein’s website by visiting www.henryschein.com/IRwebcasts. In addition, a replay will be available beginning shortly after the call has ended for a period of one week.

About Henry Schein, Inc.

Henry Schein, Inc. (Nasdaq: HSIC) is a solutions company for health care professionals powered by a network of people and technology. With more than 19,000 Team Schein Members worldwide, the Company's network of trusted advisors provides more than 1 million customers globally with more than 300 valued solutions that help improve operational success and clinical outcomes. Our Business, Clinical, Technology, and Supply Chain solutions help office-based dental and medical practitioners work more efficiently so they can provide quality care more effectively. These solutions also support dental laboratories, government and institutional health care clinics, as well as other alternate care sites.

Henry Schein operates through a centralized and automated distribution network, with a selection of more than 120,000 branded products and Henry Schein private-brand products in stock, as well as more than 180,000 additional products available as special-order items.

A FORTUNE 500 Company and a member of the S&P 500® index, Henry Schein is headquartered in Melville, N.Y., and has operations or affiliates in 31 countries and territories. The Company's sales reached $10.1 billion in 2020, and have grown at a compound annual rate of approximately 12 percent since Henry Schein became a public company in 1995.

For more information, visit Henry Schein at www.henryschein.com, Facebook.com/HenrySchein, and @HenrySchein on Twitter.

Cautionary Note Regarding Forward-Looking Statements and Use of Non-GAAP Financial Information

In accordance with the “Safe Harbor” provisions of the Private Securities Litigation Reform Act of 1995, we provide the following cautionary remarks regarding important factors that, among others, could cause future results to differ materially from the forward-looking statements, expectations and assumptions expressed or implied herein. All forward-looking statements made by us are subject to risks and uncertainties and are not guarantees of future performance. These forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance and achievements or industry results to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These statements include EPS guidance and are generally identified by the use of such terms as “may,” “could,” “expect,” “intend,” “believe,” “plan,” “estimate,” “forecast,” “project,” “anticipate,” “to be,” “to make” or other comparable terms. A fuller discussion of our operations, financial condition, and status of litigation matters, including factors that may affect our business and future prospects, is contained in documents we have filed with the United States Securities and Exchange Commission, or SEC, and will be contained in all subsequent periodic filings we make with the SEC. These documents identify in detail important risk factors that could cause our actual performance to differ materially from current expectations. Forward looking statements include the overall impact of the Novel Coronavirus Disease 2019 (COVID-19) on the Company, its results of operations, liquidity, and financial condition (including any estimates of the impact on these items), the rate and consistency with which dental and other practices resume or maintain normal operations in the United States and internationally, expectations regarding personal protective equipment (“PPE”) and COVID-19 related product sales and inventory levels and whether additional resurgences of the virus will adversely impact the resumption of normal operations, the impact of restructuring programs as well as of any future acquisitions, and more generally current expectations regarding performance in current and future periods. Forward looking statements also include the (i) ability of the Company to make additional testing available, the nature of those tests and the number of tests intended to be made available and the timing for availability, the nature of the target market, as well as the efficacy or relative efficacy of the test results given that the test efficacy has not been, or will not have been, independently verified under normal FDA procedures and (ii) potential for the Company to distribute the COVID-19 vaccines and ancillary supplies.

Risk factors and uncertainties that could cause actual results to differ materially from current and historical results include, but are not limited to: risks associated with COVID-19, as well as other disease outbreaks, epidemics, pandemics, or similar wide spread public health concerns and other natural disasters or acts of terrorism; our dependence on third parties for the manufacture and supply of our products; our ability to develop or acquire and maintain and protect new products (particularly technology products) and technologies that achieve market acceptance with acceptable margins; transitional challenges associated with acquisitions, dispositions and joint ventures, including the failure to achieve anticipated synergies/benefits; financial and tax risks associated with acquisitions, dispositions and joint ventures; certain provisions in our governing documents that may discourage third-party acquisitions of us; effects of a highly competitive (including, without limitation, competition from third-party online commerce sites) and consolidating market; the potential repeal or judicial prohibition on implementation of the Affordable Care Act; changes in the health care industry; risks from expansion of customer purchasing power and multi-tiered costing structures; increases in shipping costs for our products or other service issues with our third-party shippers; general global macro-economic and political conditions, including international trade agreements and potential trade barriers; failure to comply with existing and future regulatory requirements; risks associated with the EU Medical Device Regulation; failure to comply with laws and regulations relating to health care fraud or other laws and regulations; failure to comply with laws and regulations relating to the confidentiality of sensitive personal information or standards in electronic health records or transmissions; changes in tax legislation; litigation risks; new or unanticipated litigation developments and the status of litigation matters; cyberattacks or other privacy or data security breaches; risks associated with our global operations; our dependence on our senior management, as well as employee hiring and retention; and disruptions in financial markets. The order in which these factors appear should not be construed to indicate their relative importance or priority.

We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control or predict. Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction of actual results. We undertake no duty and have no obligation to update forward-looking statements.

Included within the press release are non-GAAP financial measures that supplement the Company’s Consolidated Statements of Income prepared under generally accepted accounting principles (GAAP). These non-GAAP financial measures adjust the Company’s actual results prepared under GAAP to exclude certain items. In the schedules attached to this press release, the non-GAAP measures have been reconciled to and should be considered together with the Consolidated Statements of Income. Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures.

(TABLES TO FOLLOW)

HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF INCOME
(in thousands, except per share data)
		Three Months Ended						Years Ended
		December 26,			December 28,			December 26,			December 28,
		2020			2019			2020			2019
		(unaudited)			(unaudited)
Net sales		$	3,165,725		$	2,668,941		$	10,119,141		$	9,985,803
Cost of sales			2,306,014			1,858,343			7,304,798			6,894,917
Gross profit			859,711			810,598			2,814,343			3,090,886
Operating expenses:
Selling, general and administrative			674,131			615,323			2,246,947			2,357,920
Restructuring costs (credits)			4,380			(1,059)			32,093			14,705
Operating income			181,200			196,334			535,303			718,261
Other income (expense):
Interest income			2,361			3,389			9,842			15,757
Interest expense			(11,968)			(9,333)			(41,377)			(50,792)
Other, net			(1,663)			(907)			(3,873)			(2,919)
Income from continuing operations before taxes, equity in earnings of affiliates and noncontrolling interests			169,930			189,483			499,895			680,307
Income taxes			(29,409)			(42,189)			(95,374)			(159,515)
Equity in earnings of affiliates			4,536			3,129			12,344			17,900
Net gain on sale of equity investments			1,572			186,769			1,572			186,769
Net income from continuing operations			146,629			337,192			418,437			725,461
Income (loss) from discontinued operations, net of tax			712			(747)			986			(6,323)
Net income			147,341			336,445			419,423			719,138
Less: Net income attributable to noncontrolling interests			(4,708)			(6,583)			(15,629)			(24,770)
Plus: Net loss attributable to noncontrolling interests from discontinued operations			-			-			-			366
Net income attributable to Henry Schein, Inc.		$	142,633		$	329,862		$	403,794		$	694,734
Amounts attributable to Henry Schein Inc.:
Continuing operations		$	141,921		$	330,609		$	402,808		$	700,691
Discontinued operations			712			(747)			986			(5,957)
Net income attributable to Henry Schein, Inc.		$	142,633		$	329,862		$	403,794		$	694,734
Earnings per share from continuing operations attributable to Henry Schein, Inc.:
Basic		$	1.00		$	2.27		$	2.83		$	4.74
Diluted		$	0.99		$	2.25		$	2.81		$	4.69
Earnings (loss) per share from discontinued operations attributable to Henry Schein, Inc.:
Basic		$	0.01		$	(0.01)		$	0.01		$	(0.04)
Diluted		$	-		$	(0.01)		$	0.01		$	(0.04)
Earnings per share attributable to Henry Schein, Inc.:
Basic		$	1.00		$	2.27		$	2.83		$	4.70
Diluted		$	1.00		$	2.24		$	2.82		$	4.65
Weighted-average common shares outstanding:
Basic			142,379			145,404			142,504			147,817
Diluted			143,328			147,078			143,404			149,257

HENRY SCHEIN, INC.
CONSOLIDATED BALANCE SHEETS
(in thousands, except share and per share data)
		December 26,			December 28,
		2020			2019
ASSETS
Current assets:
Cash and cash equivalents		$	421,185		$	106,097
Accounts receivable, net of reserves of $88,030 and $60,002			1,424,787			1,246,246
Inventories, net			1,512,499			1,428,799
Prepaid expenses and other			432,944			445,360
Total current assets			3,791,415			3,226,502
Property and equipment, net			342,004			329,645
Operating lease right-of-use assets, net			288,847			231,662
Goodwill			2,504,392			2,462,495
Other intangibles, net			479,429			572,878
Investments and other			366,445			327,919
Total assets		$	7,772,532		$	7,151,101
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	1,005,655		$	880,266
Bank credit lines			73,366			23,975
Current maturities of long-term debt			109,836			109,849
Operating lease liabilities			64,716			65,349
Accrued expenses:
Payroll and related			295,329			265,206
Taxes			138,671			165,171
Other			595,529			528,553
Total current liabilities			2,283,102			2,038,369
Long-term debt			515,773			622,908
Deferred income taxes			30,065			64,989
Operating lease liabilities			238,727			176,267
Other liabilities			392,781			331,173
Total liabilities			3,460,448			3,233,706
Redeemable noncontrolling interests			327,699			287,258
Commitments and contingencies
Stockholders' equity:
Preferred stock, $.01 par value, 1,000,000 shares authorized, none outstanding			-			-
Common stock, $.01 par value, 480,000,000 shares authorized, 142,462,571 outstanding on December 26, 2020 and 143,353,459 outstanding on December 28, 2019			1,425			1,434
Additional paid-in capital			-			47,768
Retained earnings			3,454,831			3,116,215
Accumulated other comprehensive loss			(108,084)			(167,373)
Total Henry Schein, Inc. stockholders' equity			3,348,172			2,998,044
Noncontrolling interests			636,213			632,093
Total stockholders' equity			3,984,385			3,630,137
Total liabilities, redeemable noncontrolling interests and stockholders' equity		$	7,772,532		$	7,151,101

HENRY SCHEIN, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(in thousands)
		Three Months Ended						Years Ended
		December 26,			December 28,			December 26,			December 28,
		2020			2019			2020			2019
		(unaudited)			(unaudited)
Cash flows from operating activities:
Net income		$	147,341		$	336,445		$	419,423		$	719,138
Income (loss) from discontinued operations			712			(747)			986			(6,323)
Income from continuing operations			146,629			337,192			418,437			725,461
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization			47,023			48,732			185,538			184,942
Impairment charge on intangible assets			18,126			-			20,275			-
Gain on sale of equity investments			(2,096)			(250,167)			(2,096)			(250,167)
Stock-based compensation expense			15,436			11,810			8,788			44,920
Provision for losses on trade and other accounts receivable			547			5,036			35,137			12,612
Benefit from deferred income taxes			(4,784)			(589)			(52,977)			(4,057)
Equity in earnings of affiliates			(4,536)			(3,129)			(12,344)			(17,900)
Distributions from equity affiliates			5,949			3,556			16,002			71,469
Changes in unrecognized tax benefits			(6,516)			(1,594)			(24,881)			1,941
Other			10,876			7,806			5,012			5,684
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable			10,509			42,695			(189,349)			(72,689)
Inventories			(5,987)			(60,391)			(31,817)			14,702
Other current assets			45,267			13,057			(6,479)			(57,291)
Accounts payable and accrued expenses			68,662			141,284			224,273			160,851
Net cash provided by operating activities from continuing operations			345,105			295,298			593,519			820,478
Net cash provided by (used in) operating activities from discontinued operations			4,743			(2,738)			5,391			(166,391)
Net cash provided by operating activities			349,848			292,560			598,910			654,087
Cash flows from investing activities:
Purchases of fixed assets			(11,030)			(27,263)			(48,829)			(76,219)
Proceeds (payments) related to equity investments and business acquisitions, net of cash acquired			(7,965)			1,214			(60,173)			(655,879)
Proceeds from sale of equity investment			2,020			296,751			14,020			307,251
Proceeds from (repayments to) loan to affiliate			208			265			(1,243)			16,713
Other			(4,296)			(1,927)			(18,794)			(14,175)
Net cash provided by (used in) investing activities from continuing operations			(21,063)			269,040			(115,019)			(422,309)
Net cash used in investing activities from discontinued operations			-			-			-			(2,064)
Net cash provided by (used in) investing activities			(21,063)			269,040			(115,019)			(424,373)
Cash flows from financing activities:
Net change in bank borrowings			(439,057)			(84,066)			45,082			(927,912)
Proceeds from issuance of long-term debt			-			-			501,421			741
Principal payments for long-term debt			(759)			(250,692)			(611,216)			(260,944)
Debt issuance costs			(196)			-			(3,879)			(391)
Debt extinguishment costs			-			-			(401)			-
Proceeds from issuance of stock upon exercise of stock options			-			-			-			34
Payments for repurchases of common stock			-			(200,000)			(73,789)			(525,000)
Payments for taxes related to shares withheld for employee taxes			(292)			(63)			(14,299)			(10,814)
Distribution received related to Animal Health Spin-off			-			-			-			1,120,000
Proceeds related to Animal Health Share Sale			-			-			-			361,090
Proceeds from (distributions to) noncontrolling shareholders			(3,891)			(1,931)			(7,886)			51,498
Acquisitions of noncontrolling interests in subsidiaries			(4,604)			-			(19,538)			(2,358)
Proceeds from (payments to) Henry Schein Animal Health Business			2,572			(2,738)			2,711			(169,295)
Net cash used in financing activities from continuing operations			(446,227)			(539,490)			(181,794)			(363,351)
Net cash provided by (used in) financing activities from discontinued operations			(4,743)			2,738			(5,391)			147,371
Net cash used in financing activities			(450,970)			(536,752)			(187,185)			(215,980)
Effect of exchange rate changes on cash and cash equivalents from continuing operations			9,875			5,993			18,382			14,394
Effect of exchange rate changes on cash and cash equivalents from discontinued operations			-			-			-			(2,240)
Net change in cash and cash equivalents from continuing operations			(112,310)			30,841			315,088			49,212
Net change in cash and cash equivalents from discontinued operations			-			-			-			(23,324)
Cash and cash equivalents, beginning of period			533,495			75,256			106,097			56,885
Cash and cash equivalents, end of period		$	421,185		$	106,097		$	421,185		$	106,097

Exhibit A - Fourth Quarter Sales
Henry Schein, Inc.
2020 Fourth Quarter
Sales Summary
(in thousands)
(unaudited)
Q4 2020 over Q4 2019
Global		Q4 2020			Q4 2019			Total Sales Growth		Foreign Exchange Growth		Local Currency Growth		Acquisition Growth		Local Internal Growth
Dental		$	1,846,372		$	1,722,154		7.2%		1.7%		5.5%		0.4%		5.1%
Medical			1,171,373			788,659		48.5%		0.3%		48.2%		0.0%		48.2%
Total Health Care Distribution			3,017,745			2,510,813		20.2%		1.3%		18.9%		0.3%		18.6%
Technology and value-added services			138,711			137,102		1.2%		0.7%		0.5%		1.2%		-0.7%
Total excluding Corporate TSA Revenue			3,156,456			2,647,915		19.2%		1.2%		18.0%		0.4%		17.6%
Corporate TSA revenues (1)			9,269			21,026		-55.9%		0.0%		-55.9%		0.0%		-55.9%
Total Global		$	3,165,725		$	2,668,941		18.6%		1.2%		17.4%		0.3%		17.1%
North America		Q4 2020			Q4 2019			Total Sales Growth		Foreign Exchange Growth		Local Currency Growth		Acquisition Growth		Local Internal Growth
Dental		$	1,058,367		$	1,061,077		-0.3%		0.1%		-0.4%		0.3%		-0.7%
Medical			1,137,313			769,135		47.9%		0.0%		47.9%		0.0%		47.9%
Total Health Care Distribution			2,195,680			1,830,212		20.0%		0.1%		19.9%		0.1%		19.8%
Technology and value-added services			119,456			117,608		1.6%		0.1%		1.5%		0.9%		0.6%
Total excluding Corporate TSA Revenue			2,315,136			1,947,820		18.9%		0.1%		18.8%		0.2%		18.6%
Corporate TSA revenues (1)			-			-		n/a		n/a		n/a		n/a		n/a
Total North America		$	2,315,136		$	1,947,820		18.9%		0.1%		18.8%		0.2%		18.6%
International		Q4 2020			Q4 2019			Total Sales Growth		Foreign Exchange Growth		Local Currency Growth		Acquisition Growth		Local Internal Growth
Dental		$	788,005		$	661,077		19.2%		4.3%		14.9%		0.7%		14.2%
Medical			34,060			19,524		74.5%		11.4%		63.1%		0.0%		63.1%
Total Health Care Distribution			822,065			680,601		20.8%		4.5%		16.3%		0.7%		15.6%
Technology and value-added services			19,255			19,494		-1.2%		4.4%		-5.6%		2.8%		-8.4%
Total excluding Corporate TSA Revenue			841,320			700,095		20.2%		4.6%		15.6%		0.6%		15.0%
Corporate TSA revenues (1)			9,269			21,026		-55.9%		0.0%		-55.9%		0.0%		-55.9%
Total International		$	850,589		$	721,121		18.0%		4.4%		13.6%		0.7%		12.9%
(1) Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health spin-off, which ended in December 2020.

Exhibit A - Full Year Sales
Henry Schein, Inc.
Full Year 2020
Sales Summary
(in thousands)
(unaudited)
Full Year 2020 over Full Year 2019
Global		Full Year 2020			Full Year 2019			Total Sales Growth		Foreign Exchange Growth		Local Currency Growth		Acquisition Growth		Local Internal Growth
Dental		$	5,912,593		$	6,415,865		-7.8%		-0.2%		-7.6%		0.4%		-8.0%
Medical			3,617,017			2,973,586		21.6%		0.0%		21.6%		0.9%		20.7%
Total Health Care Distribution			9,529,610			9,389,451		1.5%		-0.1%		1.6%		0.5%		1.1%
Technology and value-added services			514,258			515,085		-0.2%		0.1%		-0.3%		2.9%		-3.2%
Total excluding Corporate TSA Revenue			10,043,868			9,904,536		1.4%		-0.1%		1.5%		0.6%		0.9%
Corporate TSA revenues (1)			75,273			81,267		-7.4%		0.0%		-7.4%		0.0%		-7.4%
Total Global		$	10,119,141		$	9,985,803		1.3%		-0.1%		1.4%		0.6%		0.8%
North America		Full Year 2020			Full Year 2019			Total Sales Growth		Foreign Exchange Growth		Local Currency Growth		Acquisition Growth		Local Internal Growth
Dental		$	3,471,521		$	3,911,746		-11.3%		-0.1%		-11.2%		0.0%		-11.2%
Medical			3,514,670			2,894,137		21.4%		0.0%		21.4%		0.9%		20.5%
Total Health Care Distribution			6,986,191			6,805,883		2.6%		-0.1%		2.7%		0.4%		2.3%
Technology and value-added services			446,830			445,317		0.3%		-0.1%		0.4%		2.6%		-2.2%
Total excluding Corporate TSA Revenue			7,433,021			7,251,200		2.5%		0.0%		2.5%		0.5%		2.0%
Corporate TSA revenues (1)			-			4,098		n/a		n/a		n/a		n/a		n/a
Total North America		$	7,433,021		$	7,255,298		2.4%		-0.1%		2.5%		0.5%		2.0%
International		Full Year 2020			Full Year 2019			Total Sales Growth		Foreign Exchange Growth		Local Currency Growth		Acquisition Growth		Local Internal Growth
Dental		$	2,441,072		$	2,504,119		-2.5%		-0.5%		-2.0%		0.8%		-2.8%
Medical			102,347			79,449		28.8%		2.6%		26.2%		0.0%		26.2%
Total Health Care Distribution			2,543,419			2,583,568		-1.6%		-0.4%		-1.2%		0.7%		-1.9%
Technology and value-added services			67,428			69,768		-3.4%		0.9%		-4.3%		5.8%		-10.1%
Total excluding Corporate TSA Revenue			2,610,847			2,653,336		-1.6%		-0.4%		-1.2%		0.9%		-2.1%
Corporate TSA revenues (1)			75,273			77,169		-2.5%		0.0%		-2.5%		0.0%		-2.5%
Total International		$	2,686,120		$	2,730,505		-1.6%		-0.3%		-1.3%		0.8%		-2.1%
(1) Corporate TSA revenues represents sales of certain products to Covetrus under the transition services agreement entered into in connection with the Animal Health spin-off, which ended in December 2020.

Exhibit B
Henry Schein, Inc.
2020 Fourth Quarter and Full Year
Reconciliation of reported GAAP net income from continuing operations and
diluted EPS from continuing operations attributable to Henry Schein, Inc.
to non-GAAP net income from continuing operations and
diluted EPS from continuing operations attributable to Henry Schein, Inc.
(in thousands, except per share data)
(unaudited)
			Fourth Quarter									Full Year
								%									%
			2020			2019		Growth				2020			2019		Growth
Net Income from continuing operations attributable to Henry Schein, Inc.		$	141,921		$	330,609		(57.1)	%		$	402,808		$	700,691		(42.5)	%
Diluted EPS from continuing operations attributable to Henry Schein, Inc.		$	0.99		$	2.25		(56.0)	%		$	2.81		$	4.69		(40.1)	%
Non-GAAP Adjustments
Restructuring costs (credits) - Pre-tax (1)		$	4,380		$	(1,059)					$	32,093		$	14,705
Income tax expense (benefit) for restructuring costs (credits) (1)			(1,095)			265						(8,023)			(3,676)
Net gain on sale of equity investments (2)			(1,572)			(186,769)						(1,572)			(186,769)
Tax credit related to Animal Health spin-off (3)			-			-						-			(1,333)
Total non-GAAP adjustments to Net Income from continuing operations		$	1,713		$	(187,563)					$	22,498		$	(177,073)
Non-GAAP adjustments to diluted EPS from continuing operations		$	0.01		$	(1.28)					$	0.16		$	(1.19)
Non-GAAP Net Income from continuing operations attributable to Henry Schein, Inc.		$	143,634		$	143,046		0.4	%		$	425,306		$	523,618		(18.8)	%
Non-GAAP diluted EPS from continuing operations attributable to Henry Schein, Inc.		$	1.00		$	0.97		3.1	%		$	2.97		$	3.51		(15.4)	%

Management believes that non-GAAP financial measures provide investors with useful supplemental information about the financial performance of our business, enable comparison of financial results between periods where certain items may vary independent of business performance and allow for greater transparency with respect to key metrics used by management in operating our business. These non-GAAP financial measures are presented solely for informational and comparative purposes and should not be regarded as a replacement for corresponding, similarly captioned, GAAP measures. Earnings per share numbers may not sum due to rounding.

(1)	Represents Q4 2020 restructuring costs of $4,380, net of $1,095 tax benefit, resulting in an after-tax effect of $3,285, and 2020 restructuring costs of $32,093, net of $8,023 tax benefit, resulting in an after-tax effect of $24,070. Represents Q4 2019 restructuring credits of $1,059, net of $265 tax expense, resulting in an after-tax effect of $794, and 2019 restructuring costs of $14,705 net of $3,676 tax benefit, resulting in an after-tax effect of $11,029.
(2)	Represents a net after-tax gain on a sale of equity investments during Q4 2020 and Q4 2019.
(3)	Represents a change in estimate of $1,333 to income tax expense related to a one-time tax expense recorded in Q4 2018 as a result of a reorganization of legal entities completed in preparation for the Animal Health spin-off, which was completed on February 7, 2019.

 

View source version on businesswire.com: https://www.businesswire.com/news/home/20210217005411/en/

FAQ

What were Henry Schein's fourth quarter earnings results for 2020?

Henry Schein reported fourth quarter earnings of $3.2 billion in net sales, with GAAP net income of $141.9 million or $0.99 per diluted share.

How did Henry Schein perform in the medical segment in Q4 2020?

Medical sales for Q4 2020 were $1.2 billion, representing a 48.5% increase compared to the previous year.

What guidance has Henry Schein provided for 2021?

Henry Schein expects non-GAAP diluted EPS from continuing operations for 2021 to be at or above $3.51.

What factors influenced Henry Schein's operating margin in Q4 2020?

The operating margin was adversely affected by significant inventory adjustments and a non-cash intangible asset impairment charge of approximately $18.1 million.